#United States #Class Action #San Francisco #Hagens Berman #ADMA Biologics

ADMA Biologics Investors Targeted by Securities Fraud

In recent developments, a class action lawsuit has been filed against ADMA Biologics, Inc. (NASDAQ: ADMA) by Hagens Berman, a law firm known for defending investor rights. This lawsuit has drawn attention as it highlights severe allegations of securities fraud that claim the company misled its investors regarding its financial health and business operations. Such legal battles are not uncommon in the corporate world, but the allegations against ADMA indicate a troubling trend of misrepresentation and corporate negligence that merits closer scrutiny.

The Allegations Against ADMA Biologics

The class action claims that ADMA engaged in various deceptive practices aimed at artificially inflating its stock value. Notably, the allegations include:

• - Undisclosed Related Party Transactions: The lawsuit accuses ADMA of involving itself in transactions with related parties without disclosing them properly, a breach of trust for investors who rely on transparent information.
• - Channel Stuffing: It is alleged that the company engaged in channel stuffing practices, creating an illusion of revenue that misled investors about the real state of its financials.
• - Inadequate Internal Controls: The lawsuit argues that there were significant flaws in ADMA’s internal controls, potentially allowing these unethical practices to occur without detection.

As a consequence of these misrepresentations, investors claim they suffered substantial financial losses, particularly when the truth began to emerge.

Market Reaction Following the Revelations

The market response to the allegations was immediate and severe. Following a report by Culper Research, which highlighted the alleged channel stuffing and undisclosed transactions, ADMA's stock took a dramatic hit, falling by over 31% in just a couple of days. The stock plummeted from $11.33 on March 24, 2026, to $9.63 on March 25, leading to significant losses for investors who had trusted the integrity of the company’s financial statements. The subsequent announcement from ADMA attempting to address these claims, alongside a downgrade by Cantor Fitzgerald, further fueled a decline in stock prices, which dropped to $8.29 by March 26, 2026.

What Investors Should Do

With the lawsuit underway, affected ADMA investors are encouraged to take action. Hagens Berman is inviting those who have experienced substantial losses or who possess information relevant to the case to come forward. Those seeking guidance on their options can also reach out to the firm for insights into frequently asked questions regarding the lawsuit and potential recovery paths.

Whistleblower Information

Moreover, whistleblowers who might hold non-public data about ADMA's operations are encouraged to report their findings. Under the SEC Whistleblower program, individuals can receive significant rewards for providing information that leads to successful enforcement actions.

About Hagens Berman

Hagens Berman is a national law firm with a robust practice dedicated to holding corporations accountable for misconduct. The firm has a proven track record, having secured more than $2.9 billion for investors, consumers, and employees harmed by unethical corporate practices. They continue to advocate for transparency and fairness in corporate reporting, focusing on protecting the rights of investors.

In conclusion, as the legal proceedings proceed, it serves as a crucial reminder for investors to remain vigilant and informed about their investments. Misrepresentation within corporate statements can have devastating consequences, not just for individual portfolios, but also for the integrity of the entire financial market. Stakeholders in ADMA Biologics should keep a close eye on the unfolding events and explore their options within this class action lawsuit.